Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Severe COVID-19 Pneumonia
NCT04315480Phase 2Unknown
- Sponsor
- Università Politecnica delle Marche
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in COVID-19 pneumonia, sponsored by Università Politecnica delle Marche. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04315480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315480.